Kerry A. Rogers, MD, on Chronic Lymphocytic Leukemia: Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed or Refractory Disease

Posted: Monday, August 12, 2019

Kerry A. Rogers, MD, of The Ohio State University, discusses phase II study findings on patients with CLL who discontinued ibrutinib due to adverse events—a common problem for older patients—and how using the more selective treatment acalabrutinib may be of benefit.